Positive phase 2a results for LIB-01 showed long-lasting efficacy and safety, supporting advancement to phase 2b. Strong financial position with SEK 69.2 million cash and 85.8% equity ratio, but continued losses and need for future funding remain.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.